TARO-DESVENLAFAXINE TABLET (EXTENDED-RELEASE)
Država: Kanada
Jezik: engleski
Izvor: Health Canada
Svojstava lijeka
(SPC)
19-10-2022
Neki dokumenti za ovaj proizvod trenutno nisu dostupni, možete poslati zahtjev u našu korisničku službu i mi ćemo vas obavijestiti čim ih budemo mogli dobiti.
Pošalji zahtjev.
Pošalji zahtjev.
Aktivni sastojci:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
Dostupno od:
TARO PHARMACEUTICALS INC
ATC koda:
N06AX23
INN (International ime):
DESVENLAFAXINE
Doziranje:
100MG
Farmaceutski oblik:
TABLET (EXTENDED-RELEASE)
Sastav:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100MG
Administracija rute:
ORAL
Jedinice u paketu:
15G/50G
Tip recepta:
Prescription
Proizvod sažetak:
Active ingredient group (AIG) number: 0152509002; AHFS:
Status autorizacije:
APPROVED
Datum autorizacije:
2022-10-20
Svojstava lijeka
PRODUCT MONOGRAPH
PR TARO-DESVENLAFAXINE
desvenlafaxine extended-release tablets
50 mg and 100 mg desvenlafaxine (as desvenlafaxine succinate
monohydrate
)
Antidepressant
Taro Pharmaceuticals Inc.
Date of Revision:
130 East Drive
OCT 19, 2022
Brampton, Ontario
L6T 1C1
Submission Control No.: 264187
_________________________________________________________________________________________
_Taro-Desvenlafaxine (desvenlafaxine succinate monohydrate) Product
Monograph _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFOR
M
ATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
............................................................................................................................11
DRUG INTERACTIONS
.............................................................................................................................21
DOSAGE AND ADMINISTRATION
.........................................................................................................24
OVERDOSAGE
...........................................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................28
STORAGE AND STABILITY
....................................................................................................................31
SPECIAL HANDLING INSTRUCTIONS
.
Pročitajte cijeli dokument
